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Abstract
Background: Cisplatin is an anti-cancer chemotherapy drug classified as an alkylating agent. It is used for the
treatment of a variety of cancers such as cervical, breast, stomach, prostate, bladder and oesophageal, to name a few.
However due to its expansive toxicity profile, patients receiving cisplatin can experience high frequency hearing loss, a
side effect known as ototoxicity. The dearth of information on the extent and severity of cisplatin-associated ototoxicity
in South Africa prevents the implementation of a context-specific audiological monitoring programme.
Methods: This study aims to determine the extent and severity of ototoxicity amongst patients with cervical cancer,
receiving cisplatin-based chemotherapy and hence the feasibility of an ototoxicity monitoring program in the province
of KwaZulu-Natal, South Africa. A concurrent mixed methods design will be employed in the study. This longitudinal
study will involve interviewing oncology nurses, oncologists, pharmacists and audiologists to assess the level of
awareness to ototoxicity, as well as conducting diagnostic audiological evaluations at regular intervals on 78 patients
with cervical cancer to ascertain the progression of hearing loss during and after chemotherapy. The feasibility of the
monitoring program will be assessed as a parallel process to the audiological evaluations, where patient outcomes and
cost implications to the patient and the health sector will be considered. Data will be subjected to statistical analyses
so as to strengthen knowledge in the field and inform appropriate policies, and healthcare providers.
Discussion: This study is the first longitudinal study in South Africa to determine the ototoxic effects of cisplatin
therapy on patients diagnosed with cervical cancer. Thus, the results generated from this study is likely to bring novel
information to the fore using an evidence-based approach that will influence policy and clinical practice which can
vastly improve the quality of life of patients undergoing chemotherapy. Mitigation of any further loss in the quality of
life of affected patients is of paramount importance and the data generated from this project can lay the basis for
further effective dialogue towards policy formulation on an ototoxic monitoring programme and the resultant
strengthening of health systems in limited resource settings.
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Background
Ototoxicity refers to the hearing disorder which results
from the temporary or permanent inner ear dysfunction
after treatment with an ototoxic drug [1]. One such drug
class that produces ototoxicity is the cancer chemothera-
peutic agents. Chemotherapy is a core component of
treatment for advanced cancers, when early metastasis is
known to occur. As a result, a number of different can-
cer chemotherapy regimens are administered, depending
on the type of cancer. As evidenced in Table 1 [2], a
common thread is the use of cisplatin-based chemother-
apy, as it is unique and unmatched in its effectiveness
against many cancers [3].
However, while cisplatin chemotherapy is the treat-
ment modality in advanced carcinogenesis, the resulting
toxicity profile from the use of such regimens is expan-
sive and affects the gastrointestinal, haematologic, renal
and auditory systems [4].
In the auditory system, the primary site of cisplatin
toxicity is the outer hair cells, with the basal turn of the
cochlea appearing to be most affected [5]. However, if
administration of cisplatin continues, damage to more
apical areas is likely to occur [6]. Therefore, the initial
manifestation of cisplatin-associated ototoxicity is the
elevation of high frequency audiometric thresholds [7].
Cisplatin-associated ototoxicity usually manifests as ir-
reversible, progressive, bilateral, high frequency sensori-
neural hearing loss associated with tinnitus [8]. The
degree of hearing loss is often variable and is related to
the dose. This is evident when one considers the find-
ings of Bokemeyer et al. (1998) [9], who reported per-
manent hearing loss in 20% of patients who received
cisplatin-based chemotherapy for testicular cancer.
However, the incidence of hearing loss increased to 50%
in another group of testicular cancer patients whose
dosage was increased. An increased incidence of hearing
loss in cancer patients receiving a higher dose of cis-
platin was also reported by Waters et al. (1991) [6] and
Dutta et al. (2005) [10].
While a review of the available literature revealed that
there is only one study reporting on the incidence rates
for cisplatin-associated ototoxicity in South Africa [11],
a pooled analysis of various international studies indi-
cated an overall incidence of about 62% [6]. This
phenomenon is further supported by numerous studies
highlighting the ototoxic nature of cisplatin in exposed
patients. This is indicated by Waters et al. (1992) [6],
who reported that 92% of their patients with ovarian
cancer presented with cisplatin-associated ototoxicity.
While investigating ototoxicity in patients with testicular
cancer in a study conducted in German4y between 1977
and 1981, Strumberg et al. (2002) [12] reported that 7/
30 patients presented with cisplatin-associated ototox-
icity. This was in keeping with the findings of Boke-
meyer et al. (1998) [9], who reported cisplatin
ototoxicity in more than 50% of their cohort of 86 pa-
tients with testicular cancer in a study conducted in
Hannover, Germany between 1976 and 1987. Similarly,
Kopelman et al. (1988) [13] reported that 100% of their
patients with advanced cancers showed some degree of
hearing loss, while Nagy et al. (1999) [14] revealed that
36% of the 53 patients with oesophageal, lung or head
and neck cancer presented with cisplatin-associated oto-
toxicity. Data from India also revealed similar findings
[4, 10]. Whitehorn et al. (2014) [11] reported that 55.1%
of the patients in their retrospective study developed
ototoxicity while receiving high-dose (≥60 mg/m2) cis-
platin treatment. Hence, it is evident that ototoxicity
poses a major problem to the patient receiving cisplatin
chemotherapy, as the quality of life during and after
Table 1 Types of cancers and the associated chemotherapy regimens [2]
Type of Cancer (incidence ranking) Associated chemotherapy regimen
Males
Basal cell carcinoma Topical Fluorouracil
Prostate Cancer Docetaxel and Prednisone
Squamous cell carcinoma 5-Flourouracil, Cisplatin or Carboplatin
Non-small cell lung cancer Cisplatin, and Vinorelbine, or Docetaxel, or Gemcitabine, or Etoposide
Small cell lung cancer Cisplatin or Carboplatin, Etoposide
Oesophageal Cancer Cisplatin, 5-Fluorouracil, Docetaxel, Oxaliplatin, Capecitabine
Females
Breast Doxorubicin/Cycloplosphamide, Paclitaxel, Trastuzumab, Carboplatin, 5-Fluorouracil, Epirubicin
Cervix Cisplatin, Paclitaxel, Carboplatin, Gemcitabine
Basal cell carcinoma Topical Fluorouracil
Squamous cell carcinoma 5-Flourouracil, Cisplatin or Carboplatin
Colon Oxaliplatin, Capecitabine, 5-Fluorouracil
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receiving such therapy can be negatively affected due to
hearing loss resulting in social, emotional and vocational
difficulties. Therefore, given these negative attributes, as
a result of cisplatin, one has to ensure operational pro-
cesses that will minimise the resulting co-morbidities
from the use of such drug regimens.
An audiological monitoring program can avert, to a
large extent, the reduced quality of life as a result of hear-
ing loss, since patients on such drugs can be identified
early, counselled, monitored and managed appropriately
through interventions in a logical, systematic and coherent
manner. However, there are currently no guidelines in
South Africa for audiological management of ototoxicity.
As a result, the “Guidelines for the audiological manage-
ment of individuals receiving cochleotoxic drug therapy”
developed by the American Association of Speech-
Language-Hearing Association (ASHA) [15], and re-
iterated in the “American Academy of Audiology Position
Statement and guidelines: Ototoxicity monitoring” by the
American Academy of Audiology(AAA) [16] is seen as
the current gold standard and may, consequently,
guide the Audiologist in the implementation of an
ototoxicity monitoring program within a local, re-
gional or national setting.
The ototoxicity monitoring protocol, proposed by
ASHA [15] and AAA [16] represents an aggressive, ideal
approach for monitoring ototoxicity, and is dependent
on a country’s resources. It may, therefore, not always be
feasible or suitable for a particular context. In addition,
this protocol has been proposed by researchers in devel-
oped countries and has so far remained nothing more
than an ideal for the South African Health care system,
because no programmes have previously been formally
implemented to identify and monitor ototoxicity in pa-
tients receiving cancer chemotherapy. As a result, there
is no contextually relevant research to steer the imple-
mentation of an accountable and effective ototoxicity
monitoring program in South Africa. The first step to
developing and implementing such a program is to
document the need within a specific context [17]. There-
fore, knowledge of the epidemiology of hearing loss as-
sociated with cisplatin chemotherapy would form the
basis for the implementation of such a program.
Studies in South Africa have focused on the awareness
of healthcare personnel [18, 19] and reiterated the need
for ototoxicity monitoring [1, 20]. In addition, whilst
the prevalence of cisplatin ototoxicity was reported to
be 55.1% in the Western Cape, South Africa, the study
was retrospective in nature [11] and did not consider
the use of previous ototoxic medication, which may
have a cumulative effect on the hearing loss. The
dearth of prospective data on the extent and severity
of cisplatin-associated ototoxicity in South Africa hin-
ders audiological clinical practice within the oncology
context and thus the establishment of a contextually
relevant ototoxicity monitoring programme.
As cisplatin-associated ototoxicity negatively affects qual-
ity of life, it is essential that a monitoring program, which
identifies hearing loss early, is also implemented. In
addition, it is necessary to determine the awareness of
cisplatin-associated ototoxicity amongst health care
personnel, as it has been reported to influence identification
of patients at risk and hence early identification of hearing
loss [18]. Moreover, a national programme of research and
development would be important for “formulating inte-
grated packages of care, clarifying steps to introducing
them, testing how well such packages function, and estab-
lishing the cost and health gains from the integration of ser-
vices” (p. 943) [21]. This, therefore, emphasizes the need to
evaluate the feasibility of an audiological monitoring pro-
gram within the South African context.
In light of the ototoxic nature of cisplatin and the
dearth of information regarding its associated ototox-
icity, this study seeks to evaluate hearing loss in a cohort
of patients with cervical cancer. Cervical cancer, being
the second most common cancer in South African fe-
males, has been selected due to the large number of pa-
tients receiving cisplatin chemotherapy at the
recruitment facility. In addition, it was deemed appropri-
ate to study the effects of cisplatin-associated ototoxicity
in a relatively homogenous group (i.e. there is no vari-
ability in the number and frequency of treatments; type
and dosage of other drugs administered in combination
with cisplatin, type of cancer).
Methods
Aim
To evaluate the extent of cisplatin-associated ototoxicity
in cervical cancer patients receiving chemotherapy and
the feasibility of an audiological monitoring program.
Objectives
2.2.1 To undertake a systematic review on the existence
of ototoxicity induced by cancer chemotherapeutic
regimens.
2.2.2 To determine the level of awareness of ototox-
icity amongst health care personnel and current prac-
tices for monitoring ototoxicity.
2.2.3 To determine the extent and severity of ototox-
icity amongst cervical cancer patients receiving
cisplatin-based chemotherapy.
2.2.4 To implement, and evaluate a pilot monitoring
program on ototoxicity with the feasibility of integration
into the clinical environment.
Study design
A concurrent mixed methods design will be employed in
the study, with the aim of merging the qualitative and
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quantitative data in order to provide a complete analysis
of the research problem [22]. The dominant paradigm is a
quantitative design, i.e. panel study, which is to be con-
ducted on patients diagnosed with cervical cancer and re-
ceiving cisplatin chemotherapy. Patient follow-up will be
undertaken at regular intervals to ascertain the progres-
sion of the hearing loss, if any during and after cisplatin
chemotherapy. The less dominant paradigm is the quali-
tative design, which will be used for the analysis of open-
ended questions, and the subsequent evaluation of the
feasibility of an audiological monitoring program through
the use of the researcher’s field notes recorded during the
implementation of the ototoxicity monitoring programme.
Therefore, quantitative methodologies will be used for ob-
jectives 1, 2 and 3, while both quantitative and qualitative
methodologies will be used for objective 4.
Study population
The study will be conducted at Grey’s Hospital in the
province of KwaZulu-Natal, South Africa. This is a refer-
ral hospital providing 20% regional and 80% tertiary ser-
vices. It is also one of the main referral centres for
cancer patients. In addition, the hospital also has an
Audiology department; therefore, patients will not have
to travel to other facilities for the audiological
assessments.
The study population will comprise of:
1. Oncologists, nurses at the oncology clinic,
pharmacists and audiologists employed at the
hospital,
2. Patients diagnosed with cervical cancer and about to
commence with cisplatin-based chemotherapy.
Sampling strategy
Sampling would involve targeting all oncology clinic
personnel, pharmacists, and audiologists as well as pa-
tients with cervical cancer at the hospital. There are cur-
rently 9 oncology nurses, 3 oncologists, and 4 medical
doctors in the oncology department, 4 audiologists and
13 pharmacists at the site; therefore all will be targeted.
All patients with cervical cancer, commencing with
cisplatin-based chemotherapy and meeting the inclusion
criteria will be eligible for the study.
Inclusion Criteria
 Adults i.e. ≥18 years of age.
 Positive diagnosis of cervical cancer,
 Commencing with the first cycle of chemotherapy.
Exclusion Criteria
 Patients presenting with profound hearing loss at
baseline assessment (as it may not be possible to
determine if a significant hearing loss, as described
by ASHA [15] develops).
 Patients who have previously received cisplatin
chemotherapy (as the previous chemotherapy
treatment may also contribute to the current
ototoxic hearing loss).
 History of medical conditions such as tuberculosis,
and malaria (as the medications used in the
treatment of these conditions are ototoxic and may,
therefore, confound the results).
 History of brain metastases as this may result in
neurological complications and may thus confound test
results.
Sample size
A sample size of 78 achieves 80% power to detect a mod-
erate effect size (W) of 0.3 using a 2 degrees of freedom
(i.e. 2 groups) Chi-Square Test with a significance level (α)
of 0.05 [23]. All new patients will be screened until the
sample size is achieved. In addition, since attrition is a dis-
advantage of a longitudinal study [24] the researcher will
attempt to account for it, by including a large number of
participants at the onset of the study. An interim analysis
will be conducted once half the sample size is enrolled.
Sample size calculations are as follows:
F tests - ANOVA: Repeated measures, between factors
Analysis: A priori: Compute required sample size
Input: Effect size f = 0.25
α err prob = 0.05
Power (1-β err prob) = 0.80
Number of groups = 2
Number of measurements = 5
Corr among rep measures = 0.5
Output: Noncentrality parameter λ = 8.125
Critical F = 3.967
Numerator df = 1.000
Denominator df = 76.000
Total sample size = 78
To account for attrition of 10%, the study intended to
recruit 86 participants at the outset or until the desired
sample size of 78 was achieved.
Data collection
Objective 1: Systematic review
Data for the systematic review will be identified on
Pubmed, Science Direct, Ebsco Host and Google Scholar
for all medical research published in English-language
journals up to December 2014 using the search terms
“ototoxicity”, “cisplatin”, “chemotherapy” and “hearing
loss”. Observational study designs (i.e. cross sectional
and Cohort studies) will be accepted, provided that the
intervention is cisplatin-based chemotherapy, the partic-
ipants have been diagnosed with cancer and the
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outcome is hearing loss. The primary investigator and
the supervisors will screen all the references to be in-
cluded in the systematic review. If data is duplicated in
more than one study, the most recent study will be in-
cluded. A standardized reporting form will be used to
abstract the following data from each publication: refer-
ence (first author, year of publication), study design,
country in which study was performed, number of par-
ticipants, variables examined, covariate adjustment, and
methods used for ototoxicity monitoring.
Objective 2: Health care personnel’s knowledge of
ototoxicity and current monitoring practices
Oncology clinic personnel i.e. oncologists and oncology
nurses, will be provided with a self-administered ques-
tionnaire following informed consent. It is expected that
the questionnaire will take approximately 10 min to
complete. The questionnaire, adapted from de Andrade
et al. (2009) (see Additional file 1), will include questions
related to the following areas: clinical experience, man-
agement of patients on chemotherapy, ototoxicity and
monitoring program.
Pharmacists will also be provided with a self-
administered questionnaire (see Additional file 2) follow-
ing informed consent. It is expected that the question-
naire will take approximately 10 min to complete. The
questionnaire will include questions related to the fol-
lowing areas: experience, identification of patients at risk
for hearing loss, ototoxicity and monitoring program.
The resident audiologists will be interviewed
individually using a structured questionnaire (see
Additional file 3). The interview will last approximately
30 min and will be audio recorded. The following
general aspects will be covered during the interview:
clinical experience, description of client base, ototoxicity
and the ototoxicity monitoring program.
Objective 3: Audiological assessment for ototoxicity
Patients meeting the inclusion criteria will be invited to
participate in the study. Following informed consent,
patients will undergo audiological assessment through a
battery of five tests prior to commencement of
chemotherapy. These tests are routine procedures,
considered non painful with minimum discomfort to the
patient. Patients with cervical cancer undergo cisplatin
chemotherapy cycles weekly for a maximum period of 6
weeks. Patient follow-up will, therefore, be conducted at
the beginning of the fourth cycle and then at 1, 3 and
6 months after their last chemotherapy cycle (see Fig. 1).
The monitoring audiometry will be conducted prior to
the fourth cycle of chemotherapy, as this is generally the
mid-point of the treatment regimen for the patient with
cervical cancer. The 3-month follow-up audiological
evaluation will be conducted as it would permit deter-
mining when an ototoxic hearing loss develops and
would thus inform the ototoxicity monitoring
programme. All study appointments will be coordinated
using the oncology clinic register. However, patients will
be encouraged to schedule an audiological evaluation be-
tween scheduled appointments, if they experience any
otologic symptoms.
Audiological testing for participants who are
responsive or whose responses are limited, would
involve the following procedures:
 Review of patient’s medical records (for
confirmation of diagnosis and medication),
 interview,
 otoscopic examination,
 immittance audiometry (tympanometry and acoustic
reflex threshold testing),
 pure tone audiometry (air conduction and bone
conduction),
State hospital in 
Kwazulu-Natal, 
South Africa
Patients with cervical 
cancer
Inclusion criteria
NoYes
Informed consent NoYes
1. Baseline testing prior 
to chemotherapy
3. Post-treatment 
audiometry 1 month after 
completion of 
chemotherapy
4. Post treatment 
audiometry 3 months after 
completion of 
chemotherapy
5. Post-treatment 
audiometry 6 months after 
completion of 
chemotherapy
2. Monitoring audiometry prior to fourth cycle of 
chemotherapy
Fig. 1 Data collection process for objective 3
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 speech audiometry,
 Distortion product otoacoustic emission testing
(DPOAEs) and
 Counselling and referral to Otolaryngologist (if
significant changes in threshold identified).
Audiological testing for participants who are non-
responsive would involve the following procedures:
 Review of patient’s medical records (for
confirmation of diagnosis and medication),
 otoscopic examination,
 immittance audiometry (tympanometry and acoustic
reflex threshold testing),
 DPOAEs and,
 Counselling and referral to Otolaryngologist (if
significant changes in threshold identified).
Therefore, only objective audiological tests will be
used.
Prior to the commencement of each audiological
procedure, appropriate instructions will be provided to
the participants. The entire battery of audiological tests
is estimated to take approximately 45 min. Patients
expressing fatigue will be afforded short breaks before
continuation. The audiological procedures indicated for
ototoxicity monitoring will be utilized [15, 25] (see
Additional file 4). The case history questionnaire, used
in the study appears in Additional file 5, while all
audiological results will be recorded on an audiogram,
designed by the researcher for the purpose of the study
(see Additional file 6). Information on the risk factors
for ototoxic hearing loss will be documented during the
case history interview. This questionnaire will also
include questions on tinnitus, and caters for information
related to concurrent use of antioxidants or dietary
supplements by asking the patient about the use of all
other medication apart from cisplatin.
All audiometric test results will be determined
according to the norms (see Additional file 7). On the
identification of a significant hearing loss, an
audiological retest will be conducted within 24 h to
verify the change [15]. On identification of a reduction
in the hearing ability, participants will be counselled
regarding treatment options such as compensatory
communication strategies, as well as rehabilitation
technology options and referred to the necessary
medical personnel. Participants will also be encouraged
to stay away from noisy environments as it would
exacerbate the hearing loss.
Objective 4: Monitoring program
Patients will be monitored upon recruitment using the
six fundamental elements of ototoxicity monitoring i.e.
audiometric criteria for cochleotoxicity, identification of
patients, pre-treatment counselling regarding the poten-
tial effects of the treatment on the auditory system, base-
line testing prior to treatment, monitoring tests at
intervals suitable to enable the earliest detection of the
hearing loss, and follow up tests at intervals suitable to
determine post treatment hearing status.
The ASHA [15] criteria will be used to identify
significant ototoxic hearing loss. Identification of
patients at risk for ototoxic hearing loss will be
facilitated by conducting an information session with
oncology clinic personnel and pharmacists. The nurse
personnel will identify and inform the researcher of
patients requiring ototoxicity monitoring, and assist with
tracking patients. The researcher, together with the
nurse will coordinate test schedules with treatment.
Pre-treatment counselling will be provided by the re-
searcher. This would involve explaining the potential
effects of the treatment on the auditory system, as
well as the purpose, benefits, and procedures involved
with ototoxicity monitoring. The next three compo-
nents of the monitoring program i.e. the audiological
evaluations would be conducted, as indicated for ob-
jective 3.
Apart from monitoring patient outcomes, the following
parameters relating to feasibility will also be assessed as a
parallel process: number of patients with cervical cancer
on cisplatin chemotherapy, number of patients presenting
with cisplatin-associated ototoxicity, cost implications
with regard to personnel, equipment and the patient with
cervical cancer as well as the benefit of such a programme.
Data for this objective will be recorded on a tracking
document together with field notes. Oncology clinic
personnel and pharmacists will be required to complete a
questionnaire (see Additional file 8), and the researcher’s
field notes will also be used to determine the feasibility of
the monitoring program. In addition, participants with
cervical cancer will be required to complete a question-
naire post the monitoring program to determine patient
satisfaction (see Additional file 9).
Data analysis
A statistician from the University of KwaZulu-Natal will
assist with the statistical analysis of data.
Objective 1: Systematic review
A chi-square test for heterogeneity will be undertaken
for the included studies. If heterogeneity is found, then a
sensitivity analysis will be undertaken to identify factors
that can explain it. A funnel plot will be used to assess
the potential for publication bias. Meta-analysis will be
undertaken using a random effects model.
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Objective 2: Health care personnel’s knowledge of
ototoxicity and current monitoring practices
Thematic analysis will also be used and common themes
will be highlighted and grouped together to establish
major themes in the analysis of the interviews with the
audiologists and the open ended questions of the
questionnaires. Descriptive statistics will be used to
analyze the data. The goal of the descriptive statistics
will be to provide a summary measure of some
characteristic of the sample data [26].
Descriptive analysis methods will be used in terms of
percentage counts, bar graphs and pie charts to analyse
the results obtained in the study. The awareness
categories will be obtained using a Likert scale. The data
will then converted into percentages and frequency
counts to allow for interpretation. The following criteria
were developed in order to evaluate the level of
awareness of hearing loss induced by cancer
chemotherapy amongst healthcare personnel. The
researcher classified awareness into four levels, namely
“poor”, “average”, “good” and “excellent”. The levels
were chosen by splitting the range of awareness scores
into four levels. The lowest range (0–25%) would
represent “poor” awareness, then 26–50% would
represent “average” awareness, while 51–75% would
represent “good” awareness and 76–100% would
represent “excellent” awareness. Typically, with a large
enough sample size, the minimum awareness score
would be 0% and the maximum awareness score would
be 100%. However, with the small sample size used in
this study, the minimum and maximum values may not
be at 0% and 100% respectively, but rather will be
calculated based on the participant response rate.
Objective 3: Audiological assessment for ototoxicity
Patient screening, enrolment and follow-up will be de-
scribed using a flowchart and reasons for exclusions and
loss to follow-up reported. Descriptive statistics will be
used to summarize baseline demographic and clinical
characteristics of the participants. Each audiological as-
sessment (conventional audiometry, extended high fre-
quency audiometry and DPOAEs) will be summarized at
each time point (baseline[T0], beginning of fourth cycle
[T1], at 1 month post treatment [T2], 3 month post
treatment [T3], and 6 month post treatment [T4]). Fre-
quency distributions of quantitative data will be exam-
ined for normality. If the assumption of normality is not
satisfied, data will be transformed or non-parametric sta-
tistics used in the analysis. The degree of hearing loss
will be categorized at each time point. Quantitative
changes in hearing loss will be analysed using a mixed
model with assessment (the dependent variable); patient
and ear (random variables) and time (the independent
variable). Covariates such as age and use of antiretroviral
medication will be examined as possible confounders or
effect modifiers through logistic regression modelling to
adjust for such confounders. Severity of hearing loss
measured on an ordinal scale at baseline will be com-
pared to that at each time point using a Wilcoxon rank
sum test. Hearing loss will be dichotomized and a
proportional-odds model will be used to look at changes
over time. This model takes into account the clustered
nature of the data. A Kaplan Meier curve will be used to
examine ototoxic change and difference between the
audiology tests.
Objective 4: Monitoring programme
The feasibility of the ototoxicity monitoring programme
will be assessed by determining the cost of the
programme to the Department of Health, healthcare
personnel and the patient with cervical cancer. The need
for the ototoxicity programme will be determined by
calculating the percentage of participants with ototoxic
hearing loss. Costs will be projected by determining how
many audiologists will be required to sustain such a
programme. In addition, the costs of the audio booth and
the necessary audiological equipment will be determined
by acquiring quotes from various distributors.
Cost to the patient with cervical cancer will be
determined by analysing the time taken for each
audiological evaluation as well as if the audiological
evaluation is conducted on the same day as the
chemotherapy cycle or if the patient needs to return on a
separate day for the test. Furthermore, it will be determined
if patients will have to purchase their own hearing aids (if
required) or if the cost will be incurred by the Department
of Health. In addition, the cost to the participants with
cervical cancer will be determined by analysing the
participants’ responses to the questionnaire following the
final audiological assessment. Further, data from this
questionnaire will also be analysed to determine the benefit
of the ototoxicity monitoring program, by determining if
participants felt that they received adequate counselling
and were given the appropriate support, if required.
In addition, the field notes will be subjected to
systematic analysis according to the general themes of
context (e.g. facilities, barriers and positive aspects),
collaboration with health care personnel (attitudes,
contact, involvement, etc.) and experiences with
participants (attitudes, physical state, collaboration,
insight, etc.) [27]. The questionnaires completed by the
oncology clinic personnel, and pharmacists will be
analysed using thematic analysis and common themes
will be highlighted.
Pilot study
The questionnaire for the clinic personnel, pharmacists,
the case history questionnaire, for the patients on
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chemotherapy will be piloted on 2 oncology clinic
personnel, 2 pharmacists and 5 patients with cancer
from the hospital, to ensure its reproducibility, as these
questionnaires are considered to be newly devised
instruments. The questionnaires will be completed at
two different times (2 weeks apart) and intra-class cor-
relation coefficients will be calculated between the first
and second measurements of selected variables. The
intra-class correlation coefficients will be calculated
using the Kappa statistic.
Ethical and legal considerations
The study has adhered to the principles of the
Declaration of Helsinki and has received ethical
clearance from the Biomedical Research and Ethics
Committee of University of KwaZulu Natal (BE 064/13)
(see Additional file 10), KwaZulu-Natal Department of
Health and Greys Hospital. The study has also been
funded by the National Department of Health and ad-
ministered by the Medical Research Council (see
Additional file 11).
Discussion
This study is the first prospective follow up study in
South Africa to determine the ototoxic effects of
cisplatin therapy on patients diagnosed with cervical
cancer. Recruitment of participants will require the
assistance of the staff at the oncology department i.e.
doctors and nurses, who will inform participants of the
nature and purpose of the study. This will be expedited
through a workshop on cisplatin-associated ototoxicity
that will be facilitated by the primary researcher. Given
that this study will be undertaken in a limited resource
setting, patients do not always keep to appointments
due to the vast distances that have to be travelled.
Therefore attrition was considered and accounted for in
the sample size calculation. Further, the primary re-
searcher will ensure there is telephonic contact with par-
ticipants together with the use of Short Message System
(SMS) text services on mobile phones reminding partici-
pants of appointments. This study is expected to yield
impacts in the following ways:
1. A greater understanding of ototoxicity risk amongst
patients receiving cisplatin chemotherapy;
2. Primary data to assess, evaluate and inform a
context-specific ototoxicity monitoring program
within a limited resource setting;
3. Greater awareness on the ototoxic effects of
cisplatin-associated chemotherapy amongst health
care providers and the practice of hearing conserva-
tion among affected patients.
This study is also expected to yield as outputs:
1. A Doctoral Thesis,
2. Peer-reviewed publications based on the results
obtained, and
3. A policy brief on ototoxicity monitoring within the
South African context.
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